a double blind crossover trial of the prolactin inhibitor bromocriptine in painful benign breast disease is reportedtwentynine women with cyclical mastalgia and 11 with noncyclical pain were treated with bromocriptine 5 mg daily and placebo over six menstrual cycelsassessment of response to treatment was made by a linear analogue system and clinical examination together with plasma prolactin estimationsbromocriptine produced a significant improvement in breast symptoms and a significant fall in prolactin levels in the cyclical pain group but had no effect in the noncyclical groupthese results suggest that bromocriptine offers a new and effective approach in the management of cyclical breast pain